# To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone

> **NCT05898321** · NA · UNKNOWN · sponsor: **Women's Hospital School Of Medicine Zhejiang University** · enrollment: 294 (estimated)

## Conditions studied

- Submucous Leiomyoma of Uterus

## Interventions

- **DRUG:** Zoladex
- **DRUG:** Mifepristone Oral Tablet

## Key facts

- **NCT ID:** NCT05898321
- **Lead sponsor:** Women's Hospital School Of Medicine Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05898321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05898321, "To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05898321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*